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Tissue inflammation and nitric oxide-mediated
alterations in cardiovascular function are major
determinants of endotoxin-induced insulin
resistance
Lawrence M. House II1,2, Robert T. Morris1,3, Tammy M. Barnes1,4, Louise Lantier1, Travis J. Cyphert1,
Owen P. McGuinness1* and Yolanda F. Otero1*

Abstract
Background: Endotoxin (i.e. LPS) administration induces a robust inflammatory response with accompanying
cardiovascular dysfunction and insulin resistance. Overabundance of nitric oxide (NO) contributes to the vascular
dysfunction. However, inflammation itself also induces insulin resistance in skeletal muscle. We sought to investigate
whether the cardiovascular dysfunction induced by increased NO availability without inflammatory stress can promote
insulin resistance. Additionally, we examined the role of inducible nitric oxide synthase (iNOS or NOS2), the
source of the increase in NO availability, in modulating LPS-induced decrease in insulin-stimulated muscle
glucose uptake (MGU).
Methods: The impact of NO donor infusion on insulin-stimulated whole-body and muscle glucose uptake
(hyperinsulinemic-euglycemic clamps), and the cardiovascular system was assessed in chronically catheterized,
conscious mice wild-type (WT) mice. The impact of LPS on insulin action and the cardiovascular system were
assessed in WT and global iNOS knockout (KO) mice. Tissue blood flow and cardiac function were assessed using
microspheres and echocardiography, respectively. Insulin signaling activity, and gene expression of pro-inflammatory
markers were also measured.
Results: NO donor infusion decreased mean arterial blood pressure, whole-body glucose requirements, and
MGU in the absence of changes in skeletal muscle blood flow. LPS lowered mean arterial blood pressure and
glucose requirements in WT mice, but not in iNOS KO mice. Lastly, despite an intact inflammatory response,
iNOS KO mice were protected from LPS-mediated deficits in cardiac output. LPS impaired MGU in vivo, regardless
of the presence of iNOS. However, ex vivo, insulin action in muscle obtained from LPS treated iNOS KO animals was
protected.
Conclusion: Nitric oxide excess and LPS impairs glycemic control by diminishing MGU. LPS impairs MGU by both the
direct effect of inflammation on the myocyte, as well as by the indirect NO-driven cardiovascular dysfunction.
Keywords: Nitric oxide, Inflammation, Insulin resistance, Endotoxemia
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Introduction
Blood glucose regulation is a critical process during inflammatory states, such as blood stream infection. Improved glycemic control in the critically-ill decreases
morbidity and mortality, but overly tight regulation of
blood glucose poses an increased risk for hypoglycemia
[1, 2]. Understanding physiologic factors driving insulin
resistance in endotoxemia may direct efficacious glucose
control strategies during inflammatory states.
Skeletal muscle is the tissue with the largest glucose
uptake capacity in both humans and mice [3]. Impaired
insulin-stimulated muscle glucose uptake (MGU) is a
hallmark of insulin resistant states many of which can be
induced by inflammation, obesity, diabetes, and vascular
dysfunction [4–6]. Three steps are necessary for MGU:
substrate delivery to muscle tissue, sarcolemmal transport,
and finally myocyte metabolism (glycolysis, oxidation or
storage) of glucose. Aberrations of these MGU processes
can result in glucose intolerance and insulin resistance.
In the myocyte, insulin enhances MGU by driving
GLUT-4 translocation to the cell membrane via insulin
receptor substrate (IRS)-1, and by augmenting downstream anabolic pathways [7]. Lipopolysaccharide (LPS),
a pro-inflammatory component of Gram-negative bacteria cell walls, impairs MGU by various mechanisms,
including impairing IRS-1 and Akt, which are important
regulators if muscle glucose transport and subsequent
metabolism [5, 8–10].
LPS also has potent cardiovascular effects [11, 12]. In
healthy subjects, endothelial-derived NOS is the major
source of a low level of nitric oxide (NO), that is critical
for normal regulation of the vascular system. During
inflammation, inducible nitric oxide synthase (iNOS)
activation, triggered by LPS or cytokines, generates an
overabundance of NO in the circulation. High NO levels
generated by LPS-mediated iNOS induce hypotension
and dysregulation of tissue blood flow. Interestingly,
toll-like receptor 2 activation increases systemic iNOSderived NO without the same deleterious effects of inflammatory induction, hypotension, and limited organ
perfusion seen with LPS [13]. In mice, LPS and infection
compromise tissue blood flow further by impairing cardiac mechanical and electrical function (e.g. bradyarrhythmia) [14, 15]. Lastly, LPS exerts direct effects on
the heart by inducing inflammation in cardiomyocytes
[16, 17]. Thus, the interplay between NO abundance and
systemic inflammation on cardiovascular function are
incompletely understood.
Direct effects of LPS on the myocyte have been thoroughly studied. However processes upstream of cellular
glucose uptake signaling machinery are emerging as important determinants of LPS-mediated insulin resistance
in vivo. Cytokines [18], capillary rarefaction [19], and
other processes create insulin resistance by decreasing
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skeletal muscle substrate delivery. Thus alteration in blood
flow to skeletal muscle can indirectly limit the ability of
insulin to stimulate MGU. Given the role of NO in both
physiologic and pathologic states, we hypothesized that
blood flow and cardiovascular factors are important determinants of MGU during endotoxemia.
To investigate the impact of nitric oxide-induced
cardiovascular impairments on MGU, we utilized the
hyperinsulinemic-euglycemic clamp. To simulate nitric
oxide overabundance without inflammation, we infused
sodium nitroprusside in wild-type (WT) mice and
assessed insulin-stimulated MGU. In addition, to assess
the impact of inflammation in the absence of increased
NO availability we examined the impact of LPS on
MGU in whole-body iNOS knock-out (KO, iNOS−/−)
and WT control mice.

Research design and methods
Derivation and treatment of animals

All protocols were carried out on either wild-type
(iNOS+/+) or global iNOS knockout (iNOS−/−) mice on
a C57BL/6 J background (stock 002609; Jackson Laboratories, Bar Harbor, ME). Male mice were aged 2–4
months. Ambient housing temperature was 22 °C with
12 h light–dark cycles. Mice were fed ad libitum regular
chow diet (5001 Purina Laboratory Rodent Diet) and
had free access to water. Mice were handled prior to the
date of experiments to minimize stress. All protocols for
animal use and euthanasia were approved by the Institutional Animal Care and Use Committee at Vanderbilt
University School of Medicine and were in accordance
with the National Institutes of Health guidelines.
Experimental design

Two groups of studies were performed (Fig. 1a). The
first group (Group 1) examined the effect of increased
nitric oxide availability on metabolic and cardiovascular
parameters. The second group (Group 2) examined the
impact of LPS on these parameters in WT and iNOS
knockout mice.
The first group consisted of three separate cohorts of
wild type (WT) mice in which the impact of the infusion
of a nitric oxide donor on insulin action (1A), cardiac
function (1B) and tissue blood flow (1C) was assessed. In
this group WT animals received a variable-rate infusion of
sodium nitroprusside (SNP), a NO donor molecule
(~37 μg · kg−1 · min−1), into the jugular vein to achieve
mean arterial blood pressure (MAP) of 70 mmHg or saline. In Cohort 1A the SNP infusion was initiated 90 min
before onset of hyperinsulinemic-euglycemic clamp
(Fig. 1b) to assess the impact of SNP on MGU. In a subgroup, the duration of the insulin infusion was extended
and the SNP was discontinued during the clamp to determine the reversibility of the effect of the SNP infusion on
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Fig. 1 Experimental Schematic. The impact of nitric oxide delivery (Group 1) in wild type (WT) mice and LPS (Group 2) administration in WT and
iNOS knockout mice on insulin action (hyperinsulinemic-euglycemic clamp), and cardiovascular function (echocardiography and microspheres)
(a) was assessed. Cohorts received either a nitric oxide donor (Group 1), LPS (2.0 mg/kg; Group 2), or saline. Design of hyperinsulinemic-euglycemic
clamp protocol (Group 1 and 2, Panel b) in chronically catheterized (carotid artery and jugular vein) conscious mice. Droplets indicate blood sampling
times (10 μL or 25 μL of whole blood for small and large, respectively). DG deoxyglucose, IV intravenous, KO whole-body iNOS knockout, LPS
lipopolysaccharide, MAP mean arterial blood pressure, RBCs red blood cells, SNP sodium nitroprusside

insulin action. In Group 1B, cardiac function was assessed
using echocardiography prior to and during a SNP infusion. In Group 1C the impact of SNP on tissue blood flow
was assessed using microspheres.
In Group 2, the role of iNOS on blood pressure,
glucose homeostasis, and cardiac function in response to
LPS was assessed. WT and iNOS KO mice were assigned
to one of two treatment groups: saline (SAL) or E. coli
endotoxin (LPS; E. coli 011:B4; Sigma-Aldrich, St. Louis,
MO). Five hours after the injection of either LPS
(2.0 mg/kg BW) or saline, mice were then subjected to
hyperinsulinemic-euglycemic clamp (Group 2A). In a
separate cohort (Group 2B), the impact of LPS on cardiac function was assessed using echocardiography in
WT and iNOS KO mice. Cardiac function was assessed
prior to injection of LPS and again at 3 and 5 h after
LPS injection. After echocardiography at 5 h soleus
muscle was excised and ex vivo insulin-stimulated MGU
was determined.
Surgical procedures

To allow us to assess the impact of SNP or LPS on
blood pressure, tissue blood flow, and insulin action in
conscious unstressed mice, catheters (carotid artery

and jugular vein) were inserted 4–5 days prior to an
experiment. While under anesthesia with isoflurane,
the right jugular vein and left carotid artery were catheterized and tunneled subcutaneously to the back of
the neck as previously described [20]. The catheter
ends were attached via stainless steel connectors to
tubing made of micro-renathane (0.033 in OD). The
tubing was exteriorized, sealed with stainless steel
plugs, and flushed with saline regularly to maintain patency. Animals were individually housed after surgery,
and body weight (BW) was recorded the morning of
each study. After insertion of catheters mice were
allowed 4–5 days to regain weight within 10 % of presurgical body weight (BW) before undergoing in vivo
experimentation.
Hyperinsulinemic-euglycemic clamp

Hyperinsulinemic-euglycemic clamp (Fig. 1b; Group 1A
and 2A) allowed measurement of whole-body insulin
sensitivity and MGU as previously described [21]. In this
manuscript, insulin resistance refers to decreased insulin
sensitivity. This is manifest either as a decrease in whole
body glucose requirements or a decrease in tissue specific
glucose uptake during the clamp. Chronically catheterized
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conscious mice were fasted for 5 h (from t = −300
to 0 min) prior to insulin and glucose infusion. A
bolus of 5 μCi [3-3H]-D-glucose was given after
LPS (t = −120 min) followed by a 0.05 μCi/min infusion in the jugular vein catheter throughout the remainder of the study. After a 2 h equilibrium
period of [3-3H]-D-glucose infusion, the insulin
clamp was initiated with infusion of insulin, glucose,
and reconstituted red blood cells (t = 0 min). Insulin
(Novolin U-100, Novo Novonordisk Inc., Princeton,
NJ, USA) was infused at a rate of 4.0 mU · kg−1 ·
BW−1 · min−1 for saline-treated mice. To yield similar
clamp insulin values between groups, LPS-treated animals
received insulin at a lower rate (2.0 mU · kg-1 · BW−1 ·
min−1) because LPS decreases insulin clearance [22].
Blood glucose was measured in blood obtained from
the carotid artery every 10 min by glucometer (Accu
Chek Aviva, Roche Diagnostics, Basel, CH). 50 %
Dextrose (Hospira Inc., Lake Forest, IL, USA) was infused (t = 0 min) to maintain blood glucose at 120 mg/dL.
Red blood cells from donor animals were washed with
10 % heparin saline twice then reconstituted 1:1 in
10 % heparin saline. The cells were infused continuously during the clamp (5–6 μL/min) to replace blood
collected during the clamp. After the 2 h clamp period
(t = 120 min) a 5 μCi jugular bolus of 14C-2-deoxyglucose ([2-14C] DG) was given. Blood samples for tracer
analysis were collected at the beginning of the clamp
and in the steady state (t = 80–120 min). Arterial blood
samples were also collected at t = −10, 120, and
145 min, centrifuged and the plasma was saved for
analysis of plasma insulin. At t = 145 min, animals were
terminally anesthetized by venous injection of sodium
pentobarbital (50–70 mg/kg). Soleus, gastrocnemius,
superficial vastus lateralis, white adipose tissue, heart,
liver, and brain were excised and freeze clamped in liquid
nitrogen. Tissues and plasma were stored at −80 °C for
later analysis.
To assess tracer-determined tissue glucose uptake
freeze-clamped tissues obtained at the end of the clamp
were homogenized in 0.5 % perchloric acid on ice. Homogenate was spun at 4000 rpm for 20 min in refrigerated
centrifuge. Supernatant was neutralized to pH of 7.5 and
centrifuged again at 4000 for 10 min [2-14C] DG and 14C2-deoxyglucose-6-phosphate ([2-14C] DGP) contents were
assessed via scintillation counting. To isolate [2-14C] DG
from the homogenate, [2-14C] DGP was precipitated by
addition of 0.3 N barium hydroxide and 0.3 N zinc sulfate.
Precipitate was spun at 4000 for 5 min, and scintillation
was quantified. Disintegrations per min (dpm) for homogenate containing only [2-14C] DG was subtracted from
the dpm of the homogenate containing both [2-14C] DG
and [2-14C] DGP to yield dpm of [2-14C] DGP in tissue.
Tissue specific clearance (Kg) of [2-14C] DG and an index
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of glucose uptake (Rg; μg · min−1 · g−1) was calculated as
previously described [23]:
Kg ¼

½2−14 C DGPtissue
AUC ½2−14 C DGplasma

Rg ¼ K g x ½glucoseplasma
Where [2-14C] DGP tissue is the [2-14C] DGP radioactivity (dpm/g) in the tissue, AUC [2-14C] DG plasma is
the area under the plasma [2-14C] DG disappearance
curve (dpm/ml · min), and [glucose] plasma is the average
blood glucose (μg/μL) during the experimental period
(t = 122–150 min).
To assess plasma glucose kinetics during the clamp
liquid scintillation counting was used to quantify the
radioactivity of [3-3H]-glucose and [2-14C] DG in plasma
samples. Whole-body glucose turnover rates were computed as previously described [24]. Plasma insulin was
assessed by the Vanderbilt Hormone Assay and Analytical
Services Core via radioimmunoassay. Plasma nonesterified
free fatty acids (FFA) were sampled at t = −10 and
120 min and quantified using the HR Series NEFA-HR kit
(Wako Pure Chemicals Industries, Ltd., Osaka, Japan).
Mean arterial blood pressure (MAP)

The carotid artery catheter for each mouse was connected to a blood pressure analyzer (Groups 1 and 2;
Digi-Med BPA, Louisville, KY) for the continuous measurement of mean arterial blood pressure (MAP). For
NO donor studies (Group 1) an infusion (1 μL/min) via
the jugular catheter of either saline or sodium nitroprusside (NO donor; 1.0 mg/ml; Sigma #13451) was initiated.
Previous work has demonstrated that LPS reduces MAP
by ~40 %. This study aimed to produce a similar deficit
of ~40 % in MAP following administration of NO donor
to mimic the blood pressure response to LPS (10 mg/kg).
The blood pressure protocol was designed to establish this
drop in MAP during the 1 h prior to the onset of the
clamp (Group 1A). Adjustments in the NO donor flow
rate (μL/min) were made accordingly to maintain MAP at
approximately 70 mmHg. In parallel, we performed studies where saline was infused to mimic the fluid volume infused during the NO donor infusion studies.
Body composition and echocardiography

Body composition (Group 2A) was assessed via an mq10
nuclear magnetic resonance analyzer (Bruker Optics,
Billerica, MA). Heart rate, left ventricular internal dimensions (LVID, in mm), fractional shortening, ejection
fraction, stroke volume, and cardiac output were determined in conscious mice immediately before and during
SNP (Group 1B) infusion (1 and 3 h) or following LPS
(3 and 5 h) injection (Group 2B) via echocardiography
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(Sonos 5500 system, Agilent, Andover, MA) by the
Cardiovascular Pathophysiology and Complications Core
of the Vanderbilt Mouse Metabolic Phenotyping Center
[25]. Briefly, cardiac function was assessed by transthoracic echocardiography (Sonos 5500, Agilent, Andover,
MA) with a 15-MHz high frequency linear transducer
and frame rate of 100 frames/s. After the anterior thorax
was shaved, mice were handled via the neck posteriorly,
and an ultrasound gel was applied to the cardiothoracic
region. An ultrasound probe was used to obtain Mmode echocardiographic images from the papillary
muscles via the parasternal short-axis vies. Images
were taken at a speed of 150 cm/s (maximal temporal
resolution) for heart rate measurements. All other recordings were done using digitally recorded signals
and images. Images were recorded at a depth setting of
20 mm. The following calculations were used to determine stroke volume and cardiac output (CO in μL ·
min−1) [26, 27]:


7
EDV ¼
2:4 þ LV IDd


7
3
ESV ¼ LV IDs
2:4 þ LV IDs



LV ID3d ⋅

Stroke Volume ¼ EDV−ESV
CO ¼

Stroke Volume ⋅ Heart Rate
Body Weight ⋅ 1000

where EDV and ESV are end diastolic and systolic volumes, respectively. LVIDd and LVIDs are left ventricular
internal dimensions during diastole and systole, respectively. All volume measurements are expressed in microliters (μL).
Ex vivo muscle glucose uptake (MGU)

Tracer-determined glucose uptake in excised soleus
muscle was performed as in previous studies [28].
After 5 h of in vivo LPS (or saline) exposure (Group
2B), animals were anesthetized and soleus muscles
(right and left) were rapidly removed. Following a
15 min basal incubation in a KRH buffer with pyruvate (12 mg/ml) and mannitol (91 mg/ml) in 95 %
O2: 5 % CO2, tissues were transferred to fresh media
either with or without insulin (10 mU/ml) for
30 min. Then tissues were incubated for 10 min in
the same media containing non-radiolabeled 2-deoxyD-glucose (1 mmol/L), 2-[1,2-3H] deoxy-D-glucose
(0.25 μCi/ml), and D-[1-14C] mannitol (0.16 μCi/ml)
either with or without insulin. Muscles were lysed,
the supernatant was neutralized, and radioactivity was
quantified using liquid scintillation counting.
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Immunoblotting

Skeletal muscle protein extraction was performed as in
previous studies [22]. Briefly, tissues frozen at −80 °C
were homogenized on ice in a 50 nM Tris buffer containing 1 mM EDTA, 1 mM EGTA, 10 % glycerol, 1 %
Triton X-100, at pH 7.5, and then 1 mM DTT, 1 mM
PMSF, 5 μg/ml protease inhibitor cocktail, 10 mg/ml
trypsin inhibitor, 50 mM NaF, and 5 mM NaPP was
added the day of extraction. Protein in tissue extract was
quantified using the BioRad Protein Assay (Hercules,
CA). 25 μg of protein and BioRad Precision Plus Protein
Kaleidoscope Standard were size-fractionated in 4–12 %
or 10 % SDS-Polyacrylamide gel. Proteins and standard molecular weight ladder were transferred to PVDF
membranes. Membranes were rinsed with 1.0 %
Tween in Tris-buffered saline (TBS-T) and blocked
with 5 % nonfat dried milk in TBS-T. Membranes
were incubated overnight at overnight at 4 °C with
primary antibodies: phosphor-tyrosine, IRS-1, IRβ,
phospho-Akt (Ser473), phospho-Akt (Thr308), Akt,
phospho-glycogen synthase kinase (GSK-3). After the
TBS-T wash, membranes were incubated with corresponding secondary anti-rabbit or anti-mouse peroxidase conjugated antibody. The proteins were detected
with a chemiluminescence system (GE Healthcare, Little Chalfont, UK) exposed to X-ray film (GE Healthcare). βsystem (or in (GE Hea was used for loading
control. All antibodies used were obtained from Cell
Signaling Technology (Danvers, MA). Band intensity
was quantified using ImageJ software.
Real-time quantitative PCR

Snap-frozen gastrocnemius, heart, and epididymal white
adipose tissue were homogenized in TRIzol (Ambion
RNA, Carlsbad, CA) and extracted mRNA. cDNA was
obtained from 2 μg RNA with the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster
City, CA) and stored at −20 °C. PCR amplification
through BioRad CFX system and Taqman probes for
Interleukin-6 (IL-6), Serpine-1 (plasminogen activator inhibitor (PAI)-1), Tumor necrosis factor (TNF)-α, Nitric
oxide synthase 2 (iNOS), and Chemokine (C-C motif )
ligand 2 (MCP-1) allowed mRNA quantification using
the ΔΔCt method. Gene expression was normalized
using GAPDH as a housekeeping gene. Data are Rq
normalized to iNOS+/++SAL group or Rq = 2−ΔΔCt
[ΔCt = Ct (target)-Ct (GAPDH); ΔΔCt = ΔCt (sample)ΔCt (iNOS+/++SAL)].
Tissue blood flow (microspheres)

A separate group (Group 1C) of NO donor or salinetreated mice received a para-amino hippuric acid infusion (PAH; 24 μg/g/min) and microspheres to assess
tissue blood flow. Arterial blood was collected to
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measure blood PAH [29]. Chronically-catheterized,
conscious mice were injected with 100 μl of microspheres
(Dye-Trak VII, Triton Technology, INC, San Diego, CA)
followed by 50 μl of saline into the carotid artery. After
5 min mice were anesthetized, and tissues (hind limb
muscle, liver, kidneys, small intestine including duodenum, jejunum and ileum) were excised. The tissues were
digested overnight in 1 M KOH at 60 °C and centrifuged.
The pellet containing the microspheres was washed with
TritonX-100, ethanol containing 0.2 % (v/v) HCl, and finally re-suspended in ethanol. The resulting product was
centrifuged, and cellosolve acetate (250 μL) was added to
the microsphere:ethanol solution to elute the fluorescent
dye from the microspheres; the absorbance was determined at 440 nm.
PAH clearance was used to estimate renal blood flow.
The PAH clearance (ml/kg/min) was calculated as
follows:
PAH clearance ¼

PAHi
1

½PAH  ð1−Hct Þ

Where PAHi is the PAH infusion rate (mg · kg−1 · 1H −1);
[PAH] is the arterial plasma PAH concentration (mg/ml)
and Hct is the hematocrit ratio.
Tissue (hepatic artery, small intestine and hindlimb)
blood flow was calculated as the product of the ratio of
microspheres in a tissue, relative to microspheres in
both kidneys and PAH clearance.
Statistics

Paired data in the NO donor infusion experiment was
analyzed with two-tailed Student’Pat test. Two-way
ANOVA for repeated measures data with Holm-Sidak
post hoc analysis was used to compare groups. Wholebody insulin sensitivity was assessed via linear regression of tracer-determined whole body glucose turnover
(Rd, in mg · kg−1∙min−1) against plasma insulin levels
(ng/ml). Baseline and clamp coordinates were plotted
for WT receiving saline (n = 11) or LPS (n = 9) bolus,
iNOS−/− mice receiving saline (n = 8) or LPS (n = 8)
bolus, and WT mice receiving saline (n = 8) or NO
donor (n = 8) infusion. Baseline Rd was averaged from
values assessed at 0 min and −10 min, and clamp Rd
was averaged from four values from 80–120 min. Slope
(insulin sensitivity) and ordinate-axis intercept (insulin-independent glucose disposal) for groups were
compared via 95 % confidence intervals in a mixedeffect model. Data are presented as mean averaged
from four values from 80–120 min. S either SigmaPlot
12.0 (Aspire Software International, Ashburn, VA) or
JMP 10.0 (SAS Institute, Cary, NC). Values of P < 0.05
were considered statistically significant.
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Results
NO donor lowers blood pressure and peripheral glucose
uptake (Group 1A)

Sodium nitroprusside infusion decreased MAP during
the insulin clamp (Fig. 2a). Basal blood glucose and
plasma insulin levels were similar between treatment
groups (Table 1). During the insulin clamp, the glucose
requirements (i.e., GIR) were 40 % lower for NO donorinfused mice vs. saline (Fig. 2c). However, clamp insulin
levels for NO-treated mice were lower than saline-treated
mice (Fig. 3b). Insulin sensitivity (slope) was lower for NO
donor than saline treatment (Fig. 2d). In an extended
insulin clamp, withdrawal of NO donor infusion rapidly restored GIR and arterial blood pressure levels to
pre-infusion values (Additional file 1: Figure S1). The
anatomical sites of NO-mediated insulin resistance
were localized to soleus and gastrocnemius muscles. In
addition to white adipose tissue: these tissues had significantly diminished glucose uptake during the clamp
(Fig. 3a). Glucose uptake in all other measured tissues
was lower for NO donor-treated animals, although not
statistically significant. Thus, systemic NO abundance
and the accompanying hypotension decreased peripheral glucose disposal through impaired MGU.
Cardiac function adapts during NO-mediated hypotension
(Group 1B)

Cardiac function initially fell, but recovered during NO
donor infusion (Fig. 4). Heart rate fell after 1 h vs. baseline
(Fig. 4a). Both fractional shortening and ejection fraction
diminished after 1 h of infusion, but both recovered at 3 h
(Fig. 4d & e). Cardiac output increased significantly after
3 h of NO donor infusion (Fig. 4c). The time period
of maximal cardiac impairment (i.e., 1 h of infusion
in Fig. 4) corresponded to the insulin clamp onset
(i.e., t = 0 min; see Fig. 1). Taken together, NO donormediated hypotension (Additional file 1: Figure S2) impaired cardiac performance, but cardiac output recovered.
NO donor increases blood flow to intestine, but not
skeletal muscle (Group 1C)

Since cardiac function responds dynamically to NO
overabundance, we tested whether blood flow distribution to muscle was altered. Hindlimb and hepatic artery
blood flow was unaltered (Fig. 5a). NO donor increased
intestinal blood flow but not renal blood flow (Fig. 5a &
b). Thus, NO donor infusion increased splanchnic blood
flow (hepatic artery + intestine) but did not alter hindlimb blood flow.
NO donor does not alter skeletal muscle insulin signaling
(Group 1A)

To determine the effects of NO donor infusion on insulin
signaling in skeletal muscle, we examined downstream
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Fig. 2 Mean arterial blood pressure (MAP in mmHg, Panel a), blood glucose (mg/dL, Panel b) and glucose infusion rate (GIR in mg · kg−1 · min−1,
Panel c), for saline-treated (SAL) or sodium nitroprusside (NO)-treated wild-type (WT) mice during a hyperinsulinemic-euglycemic clamp (Group 1A).
Mice were treated with NO 90 min prior to clamp onset (t = 0 min). Glucose (50 %) was infused to maintain euglycemia at 120 mg/dL during steady
state (t = 80–120 min). Insulin sensitivity was assessed as rate of whole body glucose turnover (Rg) per animal plasma insulin level (d). Data are
expressed as mean ± SEM (n = 4–7). *p < 0.05 vs. WT + SAL. Comparison of MAP (30–120 min) and GIR (80–120 min) were assessed via t-test

signaling proteins of the insulin receptor: Akt and GSK-3β
from samples obtained at the end of the clamp. The infusion of NO donor during the insulin clamp did not alter
Akt phosphorylation in plantaris muscle (Fig. 6a & c).
Similarly, GSK-3β phosphorylation did not differ between
saline and NO donor groups (Fig. 6b & d). We did not observe differences in Akt and GSK-3β phosphorylation state
in soleus muscle either (data not shown).
Table 1 Baseline plasma glucose and insulin concentrations
Group

Blood glucose (mg/dL)

Plasma insulin (ng/ml)

NO Donor vs. Saline
WT + SAL

104 ± 8

1.3 ± 0.4

WT + NO

101 ± 9

0.3 ± 0.1*

LPS vs. Saline; iNOS−/− vs. iNOS+/+ Mice
WT + SAL

96 ± 5

0.7 ± 0.2

WT + LPS

88 ± 6

0.7 ± 0.2

iNOS KO + SAL

96 ± 5

1.0 ± 0.1

iNOS KO + LPS

83 ± 6**

0.7 ± 0.3

All blood and plasma measurements were sampled 10 min before clamp
onset (i.e., t = −10 min). Data are presented as mean ± SEM. *p < 0.05 vs. WT +
SAL; **p < 0.05 vs. iNOS KO + SAL. iNOS inducible nitric oxide synthase, KO
knock-out, LPS lipopolysaccharide, NO nitric oxide donor (sodium nitroprusside),
SAL saline, WT wild-type

LPS lowers blood pressure in an iNOS-dependent manner
(Group 2A)

Intravenous LPS (2 μg/g BW) decreased MAP for WT,
but not iNOS KO mice (Fig. 7a). MAP did not differ between WT and iNOS KO mice prior to LPS injection
(109 ± 2 vs. 111 ± 2 mmHg, respectively).
LPS-mediated insulin resistance requires iNOS (Group 2A)

Basal blood glucose concentration and plasma insulin
did not differ between genotypes (Table 1, Fig. 8b).
LPS lowered basal blood glucose in WT mice
(Table 1). Saline-treated WT and iNOS KO mice had
similar glucose requirements (Fig. 7c). However, LPS
decreased glucose requirements by 30 % vs. salinetreated WT (Fig. 7d & e). In iNOS KO mice, LPS
treatment did not alter glucose requirements. This
finding paralleled whole-body Rd vs. plasma insulin
data: LPS mediated a ~60 % decrease in insulin sensitivity (i.e. decreased slope) for WT mice (Fig. 7d).
This was not observed in iNOS KO mice (Fig. 7e).
Therefore, iNOS is required for LPS-induced whole
body insulin resistance. LPS increased basal free fatty
acids in WT mice, but free fatty acids decreased to
similar levels for all groups at the end of the insulin
clamp (data not shown).
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Fig. 3 Tissue-specific tracer-determined glucose uptake (Rg) for soleus, heart, gastrocnemius (Gastroc), superficial vastus lateralis (Vastus L), epididymal white
adipose tissue (WAT) was assessed in wild-type (WT) mice 25 min after a 5 μCi bolus of 14C-2-deoxyglucose at the end of hyperinsulinemic-euglycemic
clamp (a) (Group 1A). Plasma insulin was assessed at the onset (t = −10 min) and 2 h after hyperinsulinemic-euglycemic clamping (b).
*P < 0.05 vs. WT + SAL via t-test. **p < 0.05 vs. WT + SAL at Clamp via t-test. §P <0.05 vs. Basal for same group via t-test. NS not
significant (p ≥ 0.05)

Fig. 4 Echocardiography of wild-type (WT) mice 30 min before (Basal) and 1 h and 3 h after continuous sodium nitroprusside infusion (Group 1B).
Data include (a) heart rate (in beats/min), (b) stroke volume (in μL), (c) cardiac output (in ml/min), (d) fractional shortening (%), and (e) ejection
fraction (%), and. Data are expressed as mean ± SEM (n = 3–7). *p > 0.05 vs. Basal, p > 0.05 vs. 1H, NS not significant (p ≥ 0.05)
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both via direct effects of iNOS on the myocyte, as well
as on extra-myocyte events such as substrate delivery
that are determined by alterations in the vascular
system.
LPS-induced cardiac dysfunction is iNOS-dependent
(Group 2B)

Echocardiography demonstrated genotype differences
between WT and iNOS KO mice. Compared to WT
mice, iNOS KO mice exhibited an elevated heart rate
before and after LPS injection (Fig. 9a). Stroke volume
and cardiac output were decreased by LPS injection in
WT but not iNOS KO mice (Fig. 9b & c). LPS increased
fractional shortening in both genotypes (Fig. 9d). While
iNOS KO mice had a decreased basal ejection fraction,
LPS increased ejection fraction in a parallel fashion in
both genotypes (Fig. 9e).
LPS and muscle insulin signaling in the absence of iNOS
(Group 2A)

Fig. 5 Tissue blood flow (ml · mg−1 · min−1) for muscle, liver, intestines
in saline (SAL) or sodium nitroprusside (NO)-treated wild-type (WT)
mice (a) (Group 1C). Kidney blood flow was measured as clearance
(ml · kg−1 · min−1) of para-aminohippuric acid (PAH) clearance (b).
Data are mean ± SEM (n = 3–5). *p < 0.05 vs. WT + SAL compared
by t-test. NS not significant (p ≥ 0.05)

LPS Impairs MGU Independent of iNOS in vivo (Group 2A)

Similar to NO donor-treated animals, LPS decreased
MGU in soleus, gastrocnemius, and SVL for both genotypes (Fig. 8a). LPS increased IL-6 and MCP-1 in skeletal
muscle in both WT and iNOS KO mice and it was
higher in iNOS KO (Table 2). Additionally, LPS limited
heart glucose uptake in WT mice but not in iNOS KO
mice. However, Rg in heart muscle was lower in untreated iNOS KO than WT mice, as was the gene expression of inflammatory markers (Fig. 8a, Table 2).
Alterations in cardiovascular function by LPS in WT
but not iNOS KO mice prompted us to measure blood
flow-independent MGU (Group 2B). Ex vivo insulin
stimulated MGU after in vivo LPS injection allowed
measurement of skeletal muscle insulin action independent of changes in substrate delivery. Similar to
in vivo results, LPS decreased insulin-stimulated MGU
in soleus for WT. While iNOS KO mice were only partially protected in vivo, they were completely protected
ex vivo (Fig. 8c). Taken together, LPS impairs MGU

Similar to our previous observations [22], insulinstimulated Akt phosphorylation was not decreased by
LPS in WT mice after the 120 min insulin clamp
(Fig. 10a & c). LPS treatment actually enhanced Akt
phosphorylation in iNOS KO mice. Activation of skeletal muscle insulin receptor, insulin receptor substrate-a
(IRS-1), and glycogen synthase kinase (GSK)-3β did not
differ among groups (Fig. 10b, d and Additional file 1:
Figure S3).
LPS Induces gene expression of pro-inflammatory
markers (Group 2B)

LPS increased iNOS gene expression in heart (1.0 ± 0.04
vs 5.8 ± 1.3; p < 0.05), gastrocnemius (1.0 ± 0.2 vs 3.7 ± 1;
p < 0.05) and white adipose tissue (1.0 ± 0.1 vs 3.5 ± 1;
p = 0.07) of WT mice. LPS increased the expression of
IL-6 and MCP-1 expression in heart and gastrocnemius in both WT and iNOS KO mice (Table 2). In fact,
in iNOS KO mice cardiac inflammation was amplified.
LPS increased IL-6, but not PAI-1 and TNF-α, gene
expression in white adipose tissue (Additional file 1:
Table S1).

Discussion
LPS and the accompanying inflammatory stress markedly impair insulin stimulated muscle glucose uptake as
well as induce cardiovascular dysfunction [22]. We used
the hyperinsulinemic-euglycemic clamp to determine the
role of increased nitric oxide availability and the accompanying vascular effects, in modulating insulin action
in vivo [30]. We observed that an increase in NO availability alone in the absence of an inflammatory stress
markedly impaired insulin-stimulated MGU. Moreover,
if we prevent the LPS induced increase in nitric oxide
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Fig. 6 Effects of nitric oxide (NO) donor on skeletal muscle insulin signaling in wild-type (WT) mice (Group 1A). Western blotting was performed
for plantaris muscle extract for phosphorylation (p) of Akt at Ser473 and Thr308 (a, c) and for glycogen synthase kinase (GSK) 3β phosphorylation
at Ser9 residue (b, d). Chemiluminescence on 4–12 % SDS-PAGE gels was quantified for skeletal muscle. Insulin-induced protein phosphorylation
was quantified as the ratio phosphorylation and total Akt or GSK chemiluminescence in skeletal muscle extract after a 2 h hyperinsulinemiceuglycemic clamp. β-actin was used as a loading control. Data are arbitrary units (AU) expressed as mean ± SEM (n = 7). *p < 0.05 by two-way
ANOVA. NS not significant (p ≥ 0.05)

availability, we can partially protect against the impairment in MGU and cardiovascular dysfunction despite
the accompanying pro-inflammatory environment. Thus,
the LPS-induced insulin resistance is a result of a complex interaction of the direct result of inflammation on
myocyte function, and the events occurring outside the
myocyte that are impacted by effect of NO and inflammation on the cardiovascular system.
Cardiovascular response to NO excess

To maintain a robust impact of insulin on MGU requires a healthy vascular system, which is disrupted by
LPS and the accompanying increase in NO availability.
Increased NO delivery to tissue had potent effects on
the cardiovascular function. NO donor infusion caused
persistent hypotension with transient changes in heart
rate and cardiac output. Bradycardia following NO donor
infusion in conscious mice was unexpected, but has been
reported in anesthetized rats [31, 32]. It is possible that
the prolonged infusion altered the baroreceptor response
to hypotension [33, 34]. Bradycardia after LPS injection in
mice has been observed, and contrasts with the response
in adult human sepsis, which is marked by tachycardia
[14, 35]. We used a lower dose of LPS and did not observe
bradycardia, but it is possible that bradycardia may take

longer (>16 h) to develop with the lower doses of LPS [36,
37]. The iNOS KO mice had small baseline differences
(e.g. decrease cardiac output) that may be due to differential amounts of eNOS-derived NO [38], that may have altered the response to LPS. As expected, in response to
LPS they were protected from the hypotension and the
decrease in cardiac output [39]. The echocardiographic results were collected on conscious mice, which contrasts
with other reports where anesthesia was used and the
dose and route of LPS differed, all of which can alter the
response [22, 30, 36, 40, 41]. However, the overall cardiovascular response to LPS is not solely reliant on iNOS, as
other endocrine systems and altering signaling via cardiac
ion channels can be activated [13, 37, 39, 42]. Not surprisingly, cardiovascular status during states of NO excess appears dependent upon the presence of concomitant
inflammation. It is also possible that iNOS can serve a
protective role [43]. However on balance, excess NO derived from iNOS has important effects on the cardiovascular response to LPS.
Inflammation, NO availability and control of glucose
uptake

Increased NO availability and LPS injection impaired insulin stimulated whole body glucose uptake. Both SNP
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Fig. 7 Mean arterial blood pressure (MAP in mmHg, Panel a), blood glucose (in mg/dL, Panel b), and glucose infusion rate (GIR in mg · kg−1 · min−1,
Panel c), for saline-treated (SAL) or lipopolysaccharide (LPS)-treated iNOS+/+ (WT) or iNOS−/− (KO) mice during a hyperinsulinemic-euglycemic
clamp (Group 2A). Mice were treated with LPS (2 μg/g BW) 4 h prior to clamp onset (t = 0 min). Glucose (50 %) was infused to maintain euglycemia at
120 mg/dL during steady state (t = 80–120 min). Insulin sensitivity was represented as whole-body Rg (mg · kg−1 · min−1) vs. plasma insulin level (ng/ml)
for basal and clamp time periods in iNOS+/+ (d) and iNOS−/− mice (e). Basal glucose uptake values were determined from plasma samples at −10 min
and 0 min before the onset of the clamp. Steady state (clamp) levels were determined from plasma samples at 80, 90, 100, and 120 min. MAP (a) was
summarized as mean during end of the clamp (t = 60–120 min). Data are expressed as mean ± SEM (n = 7–8). *p < 0.05 vs. WT + SAL compared by
repeated measures two-way ANOVA for MAP (30–120 min) and GIR (80–120 min)

and LPS decreased insulin action by ~50 %. Unequal
insulin levels between groups can undermine the interpretation of clamp data. To account for this, we represented whole body insulin sensitivity as the slope of
whole-body glucose turnover (Rg) vs. plasma insulin.
This simple, yet novel xy plot is useful in depicting insulin action and can facilitate interpretation of the
hyperinsulinemic-euglycemic clamp data. From this relationship, both LPS (10.8 vs 4.4; Saline vs LPS) and
SNP (10.4 vs 6.5; Saline vs. SNP) decreased the slope
(i.e. induced insulin resistance). Moreover, iNOS KO
mice were insulin resistant at baseline and LPS did not
further decrease insulin action. Interestingly, baseline
cardiac output was also decreased in iNOS KO mice,
which paralleled the decrease in insulin action. Thus
from a whole body point of view, insulin action is very
sensitive to the cardiovascular responses seen in response to iNOS activation and to the increased NO
that accompanies it.
The impairment in whole body glucose uptake by LPS
and the NO donor was paralleled by a decrease in
MGU. As we have observed previously with higher doses
of LPS, MGU decreases in multiple muscle groups of

varying fiber types, which have very different rates of
glucose uptake in response to insulin [22]. While iNOS
KO mice were partially protected from the LPS-induced
decrease in insulin-stimulated MGU in vivo, they were
completely protected ex vivo. The contrast between the
in vivo and ex vivo data highlights the impact factors
outside the myocyte that are present in vivo in determining MGU. One such signal could be a decrease in
tissue blood flow seen in vivo, which would be absent in
the ex vivo setting. Given the marked alteration in the
vascular system by LPS and systemic NO delivery tissue
flow would be expected to be altered. Microcirculatory
flow and capillary recruitment are integral processes
controlled by insulin, inflammation, and eNOS [6, 8,
44–47]. Manipulation of skeletal muscle capillary density
and tissue flow can impair MGU [19]. Surprisingly,
despite the hypotension, NO donor infusion did not
decrease hind limb blood flow. Alterations in microvascular blood flow may still be present. The microspheres would not detect alterations in microcirculatory
blood flow nor would it detect if the flow was “shunt
or non-nutritive” flow, which could bypass the myocyte [9, 48].
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Fig. 8 Tissue-specific insulin-stimulated glucose uptake (Rd in μg∙g−1∙min−1) for LPS-treated wild-type (WT) and iNOS knock-out (KO) mice (a)
(Group 2A). In vivo glucose uptake was assessed 25 min after a 5 μCi bolus of 14C-2-deoxyglucose at the end of a hyperinsulinemic-euglycemic
clamp (n = 3–7). Insulin levels in plasma (ng/ml) before and after the clamp (b). Basal and insulin-stimulated ex vivo muscle 2-DG was determined
in isolated soleus (Panel c, n = 3–6). Tissues were incubated in media with or without insulin (10 mU/ml) for 30 min, then transferred to the same
media containing 2-deoxy-D-glucose, 2-[1,2-3H] deoxy-D-glucose (2-DG, 0.25 μCi/ml), and D-[1-14C] mannitol (0.16 μCi/ml). Data are mean ± SEM.
* p < 0.05 vs. WT + SAL, † p < 0.05 vs. KO + SAL, § p < 0.05 vs. Basal for same group

Impairment in MGU and insulin signaling

Table 2 Impact of LPS on inflammatory gene expression in WT
and iNOS KO mice
Group

Heart

Gastrocnemius

Interleukin-6 gene expression
WT + SAL

1.5 ± 0.9

1.4 ± 0.8

WT + LPS

9.6 ± 3.2p = 0.07

61 ± 26*

iNOS KO + SAL

4.1 ± 2.3

1.4 ± 0.6

iNOS KO + LPS

19.6 ± 4.7**

9.5 ± 0.9***

Monocyte Chemoattractant Protein-1 (MCP)-1 gene expression
WT + SAL

1.1 ± 0.4

1.1 ± 0.3

WT + LPS

2.6 ± 0.1*

4.9 ± 2.1

iNOS KO + SAL

1.8 ± 0.7

0.6 ± 0.6

iNOS KO + LPS

6.1 ± 2.1

p = 0.07

12.1 ± 5.3**

Relative expression (Rq) of Interleukin-6 and Monocyte Chemoattractant
Protein-1 (MCP-1) gene measured in tissues excised at the end of a
hyperinsulinemic-euglycemic clamp. Data are Rq values relative to the control
group (WT + SAL). Data are mean ± SEM. *p < 0.05 vs. WT + SAL; **p < 0.05 vs.
iNOS KO + SAL; ***p < 0.05 vs. WT + LPS. iNOS inducible nitric oxide synthase,
KO knock-out, LPS lipopolysaccharide, SAL saline, WT wild-type

Despite marked decrease in MGU with LPS and NO
donor in vivo insulin signaling was intact. This is similar
to what we have previously reported, but another study
did observe a decrease in muscle insulin signaling using
much higher (20×) doses of LPS [22, 49, 50]. On the surface, it was surprising that the decrease in insulin stimulated MGU was not associated with a decrease in IRβ,
IRS1, or Akt activation in muscle. Normal insulin signaling despite marked activation of inflammatory gene expression is also surprising. But this dissociation between
signaling and MGU is manifest in iNOS KO mice, which
were partially protected with no detected attenuation of
inflammation or enhancement of insulin signaling. Exposure of animal to LPS and inflammation can directly
impair insulin action in muscle [18, 51]. We like others
observed that LPS impaired insulin-stimulated MGU
ex vivo. Inflammation, and oxidative stress impair the
ability of NO to activate phosphatidylinositol 3-kinase
(PI3-K) and mitogen activated protein kinase (MAPK)
within vascular smooth muscle cells of insulin resistant
rats and mice [52]. One possibility as to why insulin signaling was intact is that the alteration in tissue flow may
not limit insulin delivery to the myocyte to a similar extent as that of glucose. Insulin is not metabolized by the
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Fig. 9 2-D Echocardiography of wild type (iNOS+/+) and knockout (iNOS−/−) mice before (Basal) and 5 h after intraperitoneal lipopolysaccharide
(2 mg/kg LPS, IP) (Group 2B). Heart rate (in beats/min) (a), stroke volume (in μL) (b), cardiac output (in ml/min) (c), fractional shortening (%) (d),
and ejection fraction (%) (e) were determined using M-mode echocardiographic measurements. Data are expressed as mean ± SEM (n = 7–8).
* p < 0.05 vs. basal; or wild-type (iNOS+/+) vs. knock-out (KO; iNOS−/−) via two-way ANOVA

muscle so the absolute concentration seen by the myocyte would not be altered. In contrast insulin-stimulated
MGU may become flow-limited when LPS or the NO
donor is infused. Thus, one could see a decrease in
MGU, but a relatively intact insulin signaling. It could
be that with higher doses of LPS then defects of insulin
signaling can be detected [49, 50]. It is also possible
since the tissue samples were taken at the end of the
clamp, defects in the early activation in insulin signaling
could have been missed.
The fact that the NO donor induced insulin resistance was rapidly reversed (Fig. S1) after NO donor
withdrawal [53] points to processes that can be
acutely restored, such as microcirculatory flow. Thus,
the answer to why NO donor alone impairs MGU
may lie in dysregulated microcirculatory and capillary recruitment, which are known sites of regulation
of muscle insulin action [54, 55]. We examined signaling in multiple muscles with differing fiber types
and the response was similar. It is likely that multiple levels of MGU control are exerted by LPS for
all fiber types [30]. Further endeavors investigating
NO donor-induced insulin resistance should attempt
to quantify capillary recruitment. Thus, alterations in
exomyocellular factors (microcirculatory flow, extracellular

barriers) likely play an important role in manifesting in vivo
impairment in MGU.
Differential effect of NO and LPS on insulin clearance

Another novel finding of the present study is the mechanism behind NO donor and LPS driven changes in insulin clearance. NO donor-infusion increased insulin
clearance (i.e., lowered clamp insulin levels). In contrast
consistent with our prior work, LPS impaired insulin
clearance [22]. Because we anticipated the decrease in
insulin clearance with LPS we adjusted the insulin infusion rate to better match the groups. The insulin infusion rate for LPS-treated animals was half of that for
saline-treated mice (i.e., 2.0 mU/kg · min vs. 4.0 mU/kg ·
min). As LPS also decreased insulin clearance in the
iNOS knockout mice, it would suggest that NO in the
absence of a concomitant inflammatory stress has a very
different impact on insulin clearance that is present with
an inflammatory stress. We observed that NO donors
increased splanchnic blood flow (hepatic artery + intestinal blood flow), which likely contributed to the increase in insulin clearance. In contrast, LPS likely
impairs insulin clearance by a mechanism that does
not require iNOS. While low dose LPS can increase
hepatic blood flow [56, 57], LPS must have some direct
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Fig. 10 Effects of LPS on skeletal muscle insulin signaling in wild-type (WT) and iNOS knock-out (KO) mice (Group 2A). Western blotting was
performed for gastrocnemius extract for phosphorylation (p) of Akt at Ser473 (a, c), and for glycogen synthase kinase (GSK)-3β phosphorylation
at Ser9 residue (b, d). Chemiluminescence on 4–12 % SDS-PAGE gels was quantified for skeletal muscle. Insulin-induced protein phosphorylation
was quantified as the ratio phosphorylation and total Akt and GSK-3β chemiluminescence in gastrocnemius extract after a 2 h hyperinsulinemiceuglycemic clamp. β-actin was used as a loading control. Data are arbitrary units (AU) expressed as mean ± SEM (n = 8). * p < 0.05 by two-way
ANOVA

effects on hepatic removal of insulin to impair insulin
clearance. In humans, nonspecific NOS blockade increases hepatic insulin clearance [58]. Thus, the accompanying hepatic inflammation that is seen in other
diseases that affect the liver may impair hepatic insulin
extraction [21].

Conclusions
Nitric oxide is a necessary signaling molecule for insulin
action and glucose disposal [59]. Endotoxemia impairs
in vivo and ex vivo MGU in addition to cardiac output.
Thus, acute systemic inflammation impairs MGU through
both tissue inflammation and cardiovascular dysfunction.
This suggests that while inflammatory events occurring in
the myocyte can impair insulin action, in vivo the accompanying defects outside the myocyte must be targeted to
effectively improve MGU.
Additional file
Additional file 1: Table S1. Gene expression of pro-inflammatory
markers in white adipose tissue of wild type and iNOS knockout mice
treated with LPS and after the hyperinsulinemic-euglycemic clamp.
* p < 0.05 vs WT + SAL; † p < 0.05 vs KO + SAL . Figure S1. Mean arterial
blood pressure (MAP in mmHg, Panel A), glucose infusion rate

(GIR in mg · kg-1 · min-1, Panel B), and blood glucose (in mg/dL, Panel C) for
saline-treated (SAL) or sodium nitroprusside (NO)-treated wild-type (WT;
iNOS+/+) mice during experimental induction (infusion) and restoration of
hypotension in an extended (180 min) hyperinsulinemic-euglycemic clamp
(Group 1A). Mice were treated with IV saline or NO infusion 90 min prior to
clamp onset (t = 0 min). Infusion was stopped at t = 90 min (Reversal). MAP
(Panel A) was summarized as mean during infusion period (t = 0–60 min)
and reversal period (t = 90–180). Data are expressed as mean ± SEM (n = 2).
*p ≤ 0.05 vs. WT + SAL compared by t-test; NS = not significant (p ≥ 0.05).
Figure S2. Continuous mean arterial blood pressure (MAP) monitoring during
infusion of sodium nitroprusside (NO)-infused iNOS+/+ mice (Group 1B).
Figure S3. Effects of LPS on skeletal muscle insulin signaling in wild-type
(WT; INOS+/+) and iNOS knock-out (iNOS−/−) mice after a 2 h
hyperinsulinemic-euglycemic clamp (Group 2A). β-tubulin was used as
a loading control. Western blotting was performed for gastrocnemius
and vastus lateralis extract for total and tyrosine phosphorylation of
IRS1 and Insulin receptor β (IRβ).
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